Under the contract, Oxford Nutrascience will develop a number of pharmaceutical products for Ache by utilizing its own intellectual property.
Using its physician sales network around Brazil, Ache will distribute Oxford Nutrascience’s products into the fast growing consumer healthcare market.
Oxford Nutrascience CEO Nigel Theobald said working with Ache demonstrates their capability to partner with major pharmaceutical companies who are seeking product innovation.
"The big pharma companies are attracted by our ability to apply novel pharmaceutic technology to extend the lifecycle of existing branded generic medicines, which they have often invested many millions of dollars into," Theobald said.